Controlled document PF-005A
CTO DUO Phase 1 Master Formula
Record identification
- Document ID
- PF-005A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-005A
PRODUCT FORMULA CARD
SIRIAM CTO DUO – PHASE 1 (FLOW ACTIVATION)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-CTO-001 |
| MF-005 |
| PF-005A |
| CTO DUO – Phase 1 |
| C8–T4 |
| Flow Activation |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
| Description |
|---|
| Neurovascular and afferent modulation |
| C8–T4 |
| Flow activation and neurovascular support |
| Phase 1 – Flow Activation |
| Topical Magistral Cream |
2. MASTER FORMULA
All concentrations are taken directly from the uploaded CTO Phase 1 magistral fiche.
| Code |
|---|
| Official Ingredient |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| 65.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| 18.00 |
| g |
| W |
| SC-002 |
| Magnesium Chloride |
| 3.00 |
| g |
| W |
| SC-001 |
| MSM |
| 2.50 |
| g |
| W |
| SC-003 |
| D-Panthenol (Natural Heroes) |
| 0.50 |
| g |
| C |
| SC-004 |
| Vitamin E Full Spectrum (DIY) |
| 0.40 |
| g |
| L |
| BE-003 |
| Ginkgo biloba (Mattisson) |
| 1.20 |
| g |
| C |
| BE-012 |
| Rhodiola rosea Extract |
| 0.20 |
| g |
| C |
| AC-006 |
| Niacinamide |
| 1.20 |
| g |
| W |
| BE-001 |
| Boswellia serrata (WeightWorld) |
| 0.80 |
| g |
| L |
| BE-002 |
| Copaiba Oil (Aroma-Zone) |
| 0.25 |
| mL |
| C |
| SC-005 |
| Silicea Gel |
| 2.50 |
| g |
| C |
| AC-002 |
| Betaine (TMG) |
| 0.50 |
| g |
| W |
3. MANUFACTURING WORKFLOW
Step
1
2
3
4
5
6
7
8
9
10
11
This workflow follows the Lanette protocol provided in the CTO magistral fiche.
| Action |
|---|
| Complete |
| Verify raw materials and batch documentation |
| □ |
| Prepare water phase |
| □ |
| Dissolve Magnesium Chloride, MSM, Niacinamide and Betaine (TMG) |
| □ |
| Prepare lipid dispersion (Vitamin E, Boswellia, Copaiba) |
| □ |
| Emulsification |
| □ |
| Add Ginkgo biloba and Rhodiola rosea gradually |
| □ |
| Cool below 40°C |
| □ |
| Add D-Panthenol and Silicea Gel |
| □ |
| Quality Control |
| □ |
| Fill into 15 mL airless dispensers |
| □ |
| Batch Release |
| □ |
4. QUALITY CONTROL
Parameter
Appearance
Colour
Odour
Homogeneity
pH
Viscosity
Net Weight
Packaging
Quality checkpoints include complete dissolution of MSM, homogeneous magnesium distribution, absence of phase separation and air bubbles, and correct viscosity.
| Target |
|---|
| Result |
| Standard |
| Standard |
| Standard |
| Pass |
| 5.2–5.5 |
| Airless compatible |
| Standard |
| Standard |
5. BATCH RELEASE
Field
Batch Number
Production Date
Yield
Prepared by
Checked by
Released by
| Value |
|---|
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Application
Secondary Application
Additional Application
Frequency
Treatment Phase
Application zones and treatment schedule follow the uploaded protocol.
| Value |
|---|
| C8–T4 |
| Bilateral subclavicular |
| Sternum (T2–T4) |
| Parascapular (dorsal) |
| 1–2× daily |
| Weeks 1–2 |
Related documents
Platform modules